Oncology Reviews

, Volume 5, Issue 3, pp 149–155 | Cite as

BRCA1 gene expression in relation to prognostic parameters of breast cancer

  • Manal Kamal
  • Yasser H. Shaaban
  • Mohamed Shehata
  • Amr T. El-Kashif
  • Emmad E. Habib
  • Khadiga Abu Gabal
  • Samia El-Naggar
Review
  • 52 Downloads

Abstract

The tumor suppressor gene, BRCA1 has been conferred to increase the susceptibility to breast cancer in younger women. This work studied the expression of BRCA1 (mRNA) in women with breast cancer in relation to other prognostic parameters such as histological type and grade of cancer, hormone receptor status, human epidermal growth factor receptor 2 (HER2/neu) and CA15-3. Thirty patients with positive family history of breast cancer and a control group of 20 healthy subjects were also included for the study. Ribonucleic acid (RNA) extraction from breast cancer tissues was done (considered suitable for RNA extraction if 70% or more of the tissue section contained tumor) and was followed by real-time reverse transcription polymerase chain reaction. BRCA1 expression was assessed and correlated with age, histological type and grade of breast cancer, estrogen and progesterone receptor (ER, PR) status, HER2/neu expression and CA15-3 levels. The mean age of patients was 54.8 ± 10.49 years. Of the 30 breast cancer cases studied, the majority (77%) was of high histological grade and the most common histological type was infiltrating ductal carcinoma (20 cases). ER expression was positive in 53.3% of breast cancers, while PR expression was positive in 50% of cancers. BRCA1 mRNA was found in 6 patient samples (20% of the breast cancer patients) while the remaining 24 patients (80%) showed negative BRCA1 mRNA expression as well as the control group. A positive significant relationship was demonstrated between BRCA1 (mRNA) expression and high histological grade, negative estrogen and progesterone receptor status, and high levels of serum CA15-3. A significant negative correlation was found between BRCA1 mRNA expression and age (r = −0.683; p < 0.01). The study demonstrated lack of BRCA1 gene expression (mRNA) in the majority of breast cancer cases and confirmed the relationship between BRCA1 expression and parameters that determine poor prognosis in breast cancer. The results suggested that BRCA1 is seen in high-risk women known with positive family history of breast cancer.

Keywords

BRCA1 Breast cancer Receptors 

Notes

Conflict of interest

None.

References

  1. 1.
    Hill AD, Doyle JM, McDermott EW, O’Higgins NJ (1997) Hereditary breast cancer. Br J Surg 84:1334–1339PubMedCrossRefGoogle Scholar
  2. 2.
    Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (eds) (2002) Cancer incidence in five continents, vol VIII. IARC scientific publications no. 155, LyonGoogle Scholar
  3. 3.
    Jóhannsson OT, Idvall I, Anderson C, Borg A, Barkardóttir RB, Egilsson V, Olsson H (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33(3):362–371PubMedCrossRefGoogle Scholar
  4. 4.
    Karp SE, Tonin PN, Bégin LR, Martinez JJ, Zhang JC, Pollak MN, Foulkes WD (1997) Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80(3):435–441PubMedCrossRefGoogle Scholar
  5. 5.
    Brekelmans CT, Seynaeve C, Menke-Pluymers M, Brüggenwirth HT, Tilanus-Linthorst MM, Bartels CC (2006) Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17(3):391–400PubMedCrossRefGoogle Scholar
  6. 6.
    El-Tamer M, Russo D, Troxel A, Bernardino LP, Mazziotta R, Estabrook A (2004) Survival and recurrence after breast cancer in BRCA1/2 mutation carriers. Ann Surg Oncol 11(2):157–164PubMedCrossRefGoogle Scholar
  7. 7.
    King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302:643–646PubMedCrossRefGoogle Scholar
  8. 8.
    Lynch HT, Lynch J, Conway T, Watson P, Feunteun J, Lenoir G (1994) Hereditary breast cancer and family cancer syndromes. World J Surg 18:21–31PubMedCrossRefGoogle Scholar
  9. 9.
    Easton DF, Bishop DT, Ford D (1995) Breast and ovarian cancer incidence in BRCA1 mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56:265–271PubMedGoogle Scholar
  10. 10.
    Miki Y, Swensen J, Shatuck-Eidens D, Futreal AP, Harshman K, Tavtigian S (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71PubMedCrossRefGoogle Scholar
  11. 11.
    Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW (1996) BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 7:711–715PubMedGoogle Scholar
  12. 12.
    Chen CF, Li S, Chen Y, Chen PL, Sharp ZD, Lee WH (1996) The nuclear localization sequences of the BRCA1 protein interact with the importinalpha subunit of the nuclear transport signal receptor. J Biol Chem 271:32863–32868PubMedCrossRefGoogle Scholar
  13. 13.
    Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P (1996) Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77:697–709PubMedCrossRefGoogle Scholar
  14. 14.
    Yoshikawa K, Honda K, Inamoto T, Shinohara H, Yamauchi A, Suga K (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 5:1249–1261PubMedGoogle Scholar
  15. 15.
    Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, Ellis IO (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18(1):26–35PubMedCrossRefGoogle Scholar
  16. 16.
    Keshaviah A, Dellapasqua S, Rotmensz N, Lindtner J, Crivellari D, Collins J (2007) CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trial. Ann Oncol 18(4):701–708PubMedCrossRefGoogle Scholar
  17. 17.
    Molina R, Jo J, Filella X, Zanón G, Farrus B, Muñoz M (1999) C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res 19(4A):2551–2555PubMedGoogle Scholar
  18. 18.
    Ghnassia JP, Rodier JF, Eber M (2001) Elevation of CA15-3 caused by a benign tumour. Lancet Oncol 2(2):102PubMedCrossRefGoogle Scholar
  19. 19.
    Bombardieri E, Pizzichetta M, Veronesi P, Seregni E, Bogni A, Maffioli L et al (1992) CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases. Eur J Cancer 29A(1):144–146PubMedGoogle Scholar
  20. 20.
    Al-Mulla F, Abdulrahman M, Varadharaj G, Akhter N, Anim JT (2005) BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem 53:621PubMedCrossRefGoogle Scholar
  21. 21.
    Dalton LW, Page DL, Dupont WD (1994) Histologic grading of breast carcinoma: a reproducibility study. Cancer 73:2765–2770PubMedCrossRefGoogle Scholar
  22. 22.
    Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra S, Feunteun J et al (1996) Location of BRCA1 in human breast and ovarian cancer cells. Science 272:123–126PubMedCrossRefGoogle Scholar
  23. 23.
    Peintinger F, Buzdar AU, Kuerer HM, Mejia JA, Hatzis C, Gonzalez-Angulo AM, Pusztai L, Esteva FJ, Dawood SS, Green MC, Hortobagyi GN, Symmans WF (2008) Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19(12):2020–2025 Epub 2008 Jul 29PubMedCrossRefGoogle Scholar
  24. 24.
    Amirrad MF, Al-Mulla G, Varadharaj B, John T, Saji J, Anim T (2005) BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters. Med Princ Pract 14:67–72PubMedCrossRefGoogle Scholar
  25. 25.
    Kennedy RD, Quinn JE, Johnston PG, Paul Harkin D (2002) BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 360:1007–1014PubMedCrossRefGoogle Scholar
  26. 26.
    Haffty BG, Harrold E, Khan AJ et al (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359:1471–1477PubMedCrossRefGoogle Scholar
  27. 27.
    Lee WY (2002) Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset. Appl Immunohistochem Mol Morphol 10:310–315PubMedCrossRefGoogle Scholar
  28. 28.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer—experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRefGoogle Scholar
  29. 29.
    Stratton MR (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium. Lancet 349:1505–1510Google Scholar
  30. 30.
    Lakhani SR, van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF (2002) The pathology of familial breast cancer: predictive value of immuno-histochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20:2310–2318Google Scholar
  31. 31.
    Clark G (2000) Prognostic and predictive factors. In: Harris JR (ed) Diseases of the breast, vol 2. Lippincott Williams & Wilkins, Philadelphia, pp 489–514Google Scholar
  32. 32.
    Elledge RM, Fuqua SA (2000) Estrogen and progesterone receptors. In: Harris JR (ed) Diseases of the breast, vol 2. Lippincott Williams & Wilkins, Philadelphia, pp 471–488Google Scholar
  33. 33.
    Lose F, Duffy DL, Kay GF, Kedda MA, Spurdle AB (2008) Kathleen Cuningham Foundation Consortium for research into familial breast cancer; Australian Ovarian Cancer Study Management Group. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. J Natl Cancer Inst 100(21):1519–1529PubMedCrossRefGoogle Scholar
  34. 34.
    Tommasi S, Pilato B, Pinto R (2008) Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 644(1–2):64–70PubMedGoogle Scholar
  35. 35.
    Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA (1987) Alterations to either cerbB- 2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor shortterm prognosis. Oncogene 1:423–430PubMedGoogle Scholar
  36. 36.
    Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H (2005) Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 7:R93–R100PubMedCrossRefGoogle Scholar
  37. 37.
    Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22(12):2328–2335PubMedCrossRefGoogle Scholar
  38. 38.
    Robson M, Gilewski T, Haas B, Levin D, Borgen P, Rajan P et al (1998) BRCA-associated breast cancer in young women. J Clin Oncol 16(5):1642–1649PubMedGoogle Scholar
  39. 39.
    Verhoog LC, Brekelmans CT, Seynaeve C, Meijers-Heijboer EJ, Klijn JG (2000) Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer. Br J Cancer 83:384–386PubMedCrossRefGoogle Scholar
  40. 40.
    Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3):159–164PubMedCrossRefGoogle Scholar
  41. 41.
    Kloos I, Delaloge S, Chompret A et al (2001) BRCA1/2-linked breast carcinoma is a highly chemosensitive disease. Proc Annu Meet Am Soc Clin Oncol (abstr 1862)Google Scholar
  42. 42.
    Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2007) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899–23903CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Manal Kamal
    • 1
    • 6
  • Yasser H. Shaaban
    • 1
  • Mohamed Shehata
    • 1
  • Amr T. El-Kashif
    • 2
  • Emmad E. Habib
    • 2
    • 5
  • Khadiga Abu Gabal
    • 3
  • Samia El-Naggar
    • 4
  1. 1.Department of Clinical and Chemical Pathology, Faculty of MedicineCairo UniversityCairoEgypt
  2. 2.Department of Clinical Oncology, Faculty of MedicineCairo UniversityCairoEgypt
  3. 3.Department of Clinical and Chemical Pathology, Faculty of MedicineBeni-Suef UniversityBeni-SuefEgypt
  4. 4.Department of Pathology, Faculty of MedicineBeni-Suef UniversityBeni-SuefEgypt
  5. 5.Centre of Clinical Oncology, Kasr El-Eini HospitalCairo UniversityCairoEgypt
  6. 6.CairoEgypt

Personalised recommendations